TY - JOUR
T1 - WNT and β-catenin signalling
T2 - Diseases and therapies
AU - Moon, Randall T.
AU - Kohn, Aimee D.
AU - De Ferrari, Giancarlo V.
AU - Kaykas, Ajamete
N1 - Funding Information:
R.T.M. is supported as an investigator and A.K. as an associate of the Howard Hughes Medical Institute, to which we are indebted for support. We thank M. Kahn and P. Yaworsky for reviewing a draft of this manuscript. We acknowledge funding by the Alzheimer’s Association and by the National Institutes of Health. G.V.D. is funded by the Pew Latin American Fellows Program in the Biomedical Sciences, and A.D.K. is funded by the National Institutes of Health. As with any review, this one is a snapshot that is blurred by the fast pace of advancement in the field. We therefore apologize for any omissions or oversights.
PY - 2004/9
Y1 - 2004/9
N2 - WNT signalling has been studied primarily in developing embryos, in which cells respond to WNTs in a context-dependent manner through changes in survival and proliferation, cell fate and movement. But WNTs also have important functions in adults, and aberrant signalling by WNT pathways is linked to a range of diseases, most notably cancer. What is the full range of diseases that involve WNT pathways? Can inhibition of WNT signalling form the basis of an effective therapy for some cancers? Could activation of WNT signalling provide new therapies for other clinical conditions? Finally, on the basis of recent experiments, might WNTs normally participate in self-renewal, proliferation or differentiation of stem cells? If so, altering WNT I signalling might be beneficial to the use of stem cells for therapeutic means.
AB - WNT signalling has been studied primarily in developing embryos, in which cells respond to WNTs in a context-dependent manner through changes in survival and proliferation, cell fate and movement. But WNTs also have important functions in adults, and aberrant signalling by WNT pathways is linked to a range of diseases, most notably cancer. What is the full range of diseases that involve WNT pathways? Can inhibition of WNT signalling form the basis of an effective therapy for some cancers? Could activation of WNT signalling provide new therapies for other clinical conditions? Finally, on the basis of recent experiments, might WNTs normally participate in self-renewal, proliferation or differentiation of stem cells? If so, altering WNT I signalling might be beneficial to the use of stem cells for therapeutic means.
UR - http://www.scopus.com/inward/record.url?scp=4344584730&partnerID=8YFLogxK
U2 - 10.1038/nrg1427
DO - 10.1038/nrg1427
M3 - Review article
C2 - 15372092
AN - SCOPUS:4344584730
SN - 1471-0056
VL - 5
SP - 691
EP - 701
JO - Nature Reviews Genetics
JF - Nature Reviews Genetics
IS - 9
ER -